ExCEEd Orphan announces extension of partnership with Amryt to exclusively distribute Lojuxta® in 17 countries of Central and Eastern Europe (CEE)

ExCEEd Orphan Distribution d.o.o., a Croatia based fully-owned subsidiary of ExCEEd Orphan s.r.o., a company providing full business solutions for the treatment of rare diseases, signed an extension of exclusive distribution agreement with Amryt by adding Lojuxta® (lomitapide) for treatment of adult patients with homozygous familial hypercholesterolaemia to already marketed Amryt products (Filsuvez® for treatment of wounds associated with epidermolysis bullosa and Myalepta® for treatment of lipodystrophy). Under the terms of this agreement, ExCEEd Orphan will have exclusive rights to seek reimbursement, distribute and market Lojuxta® in all 17 CEE countries – Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Kosovo, Latvia, Lithuania, Montenegro, North Macedonia, Poland, Romania, Serbia, Slovakia and Slovenia.

Jiri Hermanek, CEO and Founding Partner of ExCEEd Orphan, commented:
“We are really pleased to announce further extension of already successful partnership with Amryt to bring Lojuxta® to patients suffering from homozygous familial hypercholesterolaemia in CEE countries. It perfectly fits our long-term strategy of focusing on commercialisation of highly innovative medications for rare diseases in CEE region. We are looking forward to continue working with Amryt to make their innovative treatments available to all patients in needs in our countries!”
About ExCEEd Orphan

ExCEEd Orphan was founded in 2018 by five rare disease experts from multiple Central and Eastern European (CEE) countries. The Company is focusing on innovative treatments for rare diseases and has extensive experience in launching innovative medicines in this field. The portfolio of ExCEEd Orphan includes products in therapeutic areas like haematology, neurology, immunology, and metabolic diseases.
For further information about ExCEEd Orphan, visit  www.exceedorphan.com.
About Amryt

Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a strong and growing portfolio of commercial and development assets.
For further information about Amryt, please visit www.amryt.com.

Get in touch

With real experts in CEE region.

Send us an e-mail